J.ophthalmol.(Ukraine).2021;3:49-54.

Fulltext Pdf 


http://doi.org/10.31288/oftalmolzh202134954

Received: 02 November 2020; Published on-line: 29 June 2021


Ocular manifestations in patients with hematologic malignancies

D. A. Lysenko 1, O. V. Dzhygaliuk 2, L. I. Chereshniuk 1 

1 National Pirogov Memorial Medical University, Vinnytsya; Vinnytsya (Ukraine)

2 SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine;  Odesa (Ukraine)

E-mail: dovgalenko1@ukr.net

TO CITE THIS ARTICLE:Lysenko DA, Dzhygaliuk OV, Chereshniuk  LI. Ocular manifestations in patients with hematologic malignancies. J.ophthalmol.(Ukraine).2021;3:49-54.  http://doi.org/10.31288/oftalmolzh202134954


Ocular manifestations in patients with hematologic malignancies may develop either as a primary sign of the underlying disease or as relapse in remission. In addition, ocular involvement may result from anemia, thrombocytopenia, and coagulopathy, as well as infectious lesions caused by complications developing in the patient. Moreover, ocular toxicity may develop if the patient is treated with cytostatic and/or targeted agents. The review indicates that leukemia should be ruled out in the presence of ocular lesions (especially, hemorrhagic complications and retinal and optic nerve lesions). In addition, while examining a patient in remission after therapy for hematologic malignancy, recurrent hematologic malignancy should be ruled out in the presence of ocular manifestations. Moreover, a high index of suspicion for ocular toxicity should be maintained while examining a patient treated with either conventional cytostatics or target therapy, because any ocular lesions in this patient may be manifestations of ocular toxicity, and if so, the patient requires urgent intervention or discontinuation of the therapy for underlying disease.

Keywords: leukemia, hematologic malignancies, ocular manifestations, hemorrhages, retinopathy, optic nerve

Funding: This study did not receive any funding support.

Acknowledgement: The authors thank I.L. Chereshniuk for his assistance in the search of relevant literature.

Conflict of interest statement: None declared.

 

References

1.Schachat AP, Markowitz JA, Guyer DR, Burke PJ, Karp JE, Graham ML. Ophthalmic manifestations of leukemia. Arch Ophthalmol. 1989 May;107(5):697-700. 

Crossref  PubMed

2.Talcott KE, Garg RJ, Garg SJ. Ophthalmic manifestations of leukemia. Curr Opin Ophthalmol. 2016 Nov;27(6):545-551.

Crossref  PubMed

3.Myers KA, Nikolic A, Romanchuk K, et al. Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency. Neurooncol Pract. 2017;4(1):60‐6.

Crossref  PubMed

4.Koshy J, John MJ, Thomas S, Kaur G, Batra N, Xavier WJ. Ophthalmic manifestations of acute and chronic leukemias presenting to a tertiary care center in India. Indian J Ophthalmol. 2015 Aug;63(8):659-64.

Crossref  PubMed

5.Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020 May 13;10(5):56.

Crossref  PubMed

6.Sharma H, Majumder PD, Rao C, Biswas J. A case of Acute Myeloid Leukemia masquerading as unilateral exudative detachment. Am J Ophthalmol Case Rep. 2016 Aug 12;4:47-49.

Crossref  PubMed

7.Akaike S, Kamoi K, Tezuka M, Tomizawa D, Yoshimura R, Takagi M, Ohno-Matsui K. Ocular manifestation in myeloid/NK cell precursor acute leukemia: a case report. Diagnosed by flow cytometry and PCR from aqueous humor. Medicine (Baltimore). 2016 Sep;95(38):e4967.

Crossref  PubMed

8.Pflugrath AE,  Brar VS. Bilateral optic nerve and retinal infiltration as an initial site of relapse in a child with T-cell acute lymphoblastic leukemia. Am J Ophthalmol Case Rep. 2020 Apr 10;18:100695.

Crossref  PubMed

9.Chin KJ, Kempin S, Milman T, Finger PT. Ocular manifestations of multiple myeloma: three cases and a review of the literature. Optometry. 2011;82(4):224‐230. 

Crossref  PubMed

10.Yazdanpanah O, Kaur J, Shafi I, Sarakbi HA. Diplopia as the initial symptom of multiple myeloma in a patient with sarcoidosis. BMJ Case Rep. 2020 Aug 24;13(8):e235725.

Crossref  PubMed

11.Hoehn ME, Elder JE, Estepp JH. Hematologic Disorders of the Eye. In: Levin AV, Enzenauer RW, editors. The Eye in Pediatric Systemic Disease 2017. Springer International Publishing; Cham, Switzerland: 2017. pp. 295-325).

Crossref  

12.Kunkler AL, Binkley EM, Mantopoulos D, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol. 2019;257(8):1771‐81.

Crossref  PubMed

13.de Queiroz Mendonca C, Freire MV, Viana SS, Silva Tavares, MKG, Almeida Silva, WM, Cipolotti, R. Ocular manifestations in acute lymphoblastic leukemia: a five-year cohort study of pediatric patients. Leuk Res. Leuk Res. 2019 Jan;76:24-28.

Crossref  PubMed

14.MacDonell-Yilmaz RE, Statler B, Channa P, Janigian RH Jr, Welch JG. Leukemic Infiltration of the Optic Nerve. JCO Oncol Pract. 2020;16(3):139‐141. 

Crossref  PubMed

15.Myers KA, et al. Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency. Neurooncol Pract. 2017;4(1):60‐6.Crossref  PubMed

16.Smith AG, London NJ, Pao K, Lipkowitz J, Kurup SK, Garg SJ. Leukemia presenting as serous retinal detachment. Retin Cases Brief Rep. 2014;8(4):279‐282. 

Crossref  PubMed

17.Rehak M, Feltgen N, Meier P, et al. Retinabeteiligung bei hämatologischen Erkrankungen. Ophthalmologe 2018. 115, 799–812.

Crossref  PubMed

18.Hafeez MU, Ali MH, Najib N, Ayub MH, Shafi K, Munir M, Butt NH. Ophthalmic Manifestations of Acute Leukemia. Cureus, 2019. 11(1), e3837.

Crossref  

19.Ilo OT, Adenekan AO, Alabi AS, et al. Ocular manifestations of leukaemia: A teaching hospital experience. Niger Postgrad Med J. 2019;26(4):205‐210. 

Crossref  PubMed

20.Hashemieh M, Yadgari M. Ophthalmic Manifestations of Acute Leukemia: A Review. Journal of Ophthalmic and Optometric Sciences. 2019;3(1):20-9.

Crossref  PubMed

21.Skarsgård LS, Andersson MK, Persson M, et al. Clinical and genomic features of adult and paediatric acute leukaemias with ophthalmic manifestations. BMJ Open Ophthalmol. 2019;4(1):e000362.

Crossref  PubMed

22.Kamoi K, Okayama A, Izumo S, et al. Adult T-Cell Leukemia/Lymphoma-Related Ocular Manifestations: Analysis of the First Large-Scale Nationwide Survey. Front Microbiol. 2019; 9: 3240.

Crossref  PubMed

23.Gillette TB, Cabrera MT, Tarlock K, Murphy CE, Chisholm KM, Stacey AW. Rapidly Progressive, Isolated Subretinal Leukemic Relapse: A Case Report. Ocul Oncol Pathol. 2018;4(4):220‐224.

Crossref  PubMed

24.Němčanská S, Stepanov A, Němčanský J. Ophthalmic manifestations of acute leukaemias. Oční nálezy u akutních leukémií. Cesk Slov Oftalmol. 2018;74(3):98‐101. 

Crossref  PubMed

25.Prakash A, Gupta N, Verma SK. Ocular manifestations in leukemia and myeloproliferative disorders and their association with hematological parameters. Ann Afr Med. 2016;15(3):97‐103.

Crossref  PubMed

26.Delestre F, Blanche P, Bouayed E, et al. Ophthalmic involvement of chronic lymphocytic leukemia: a systematic review of 123 cases. Surv Ophthalmol. 2020;S0039-6257(20)30085-0.

Crossref  PubMed

27.Rajagopal R, Apte RS. Seeing through thick and through thin: Retinal manifestations of thrombophilic and hyperviscosity syndromes. Surv Ophthalmol. 2016;61(2):236‐247.

Crossref  PubMed

28.Yoshida-Hata N, Katai N, Oshitari T. Ophthalmic Manifestations of Hematopoietic Malignancy. Case Rep Ophthalmol Med. 2016;2016:6074968. 

Crossref  PubMed

29.Saffra N, Gorgani F, Panasci D, Kirsch D. Diplopia and proptosis due to isolated lateral rectus plasmacytoma in a patient with multiple myeloma. BMJ Case Rep. 2019;12(7):e229178.

Crossref  PubMed

30.Lyu S, Zhang M, Gao Y. Acute bilateral retina hemorrhages beneath internal limiting membrane: An unusual ophthalmological case report of acute leukemia during complete clinical remission. Medicine (Baltimore). 2018;97(7):e0000.

Crossref  PubMed

31.Chaabani L, Doulami K. White-centred retinal hemorrhage revealing acute leukemia. Tunis Med. 2019 Jun;97(6):822‐5. https:// www.latunisiemedicale.com/article-medicale-tunisie.php?article=3596. 

32.Bhatti MT, Salama AKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye (Lond). 2018;32(2):287‐301.

Crossref  PubMed

33.Harman LE. Ophthalmic Complications Related to Chemotherapy in Medically Complex Patients. Cancer Control. 2016 Apr;23(2):150-6.

Crossref  PubMed

34.Liu CF, Francis JH, Pulido JS, Abramson J. Ocular side effects of systemically administered chemotherapy. 2018. UpToDate. Waltham, MA: UpToDate Inc. Available at:  https:// www.uptodate.com/contents/ocular-side-effects-of-systemically-administer... .

35.Vishnevskia-Dai V, Sella King S, Lekach R, Fabian ID, Zloto O. Ocular Manifestations of Leukemia and Results of Treatment with Intravitreal Methotrexate. Sci Rep. 2020 Feb 6;10(1):1994.Crossref  PubMed

36.Roop P, Angmo D, Kamble N, Tomar AS. Uncontrolled neovascular glaucoma - an alarming manifestation of chronic myeloid leukemia on imatinib therapy - a case report and review of literature. Indian J Ophthalmol. 2019;67(2):285‐7.

Crossref  PubMed

37.Levasseur SD, Tantiworawik A, Lambert Maberley DA. All-trans retinoic Acid differentiation syndrome chorioretinopathy: a case of multifocal serous neurosensory detachments in a patient with acute promyelocytic leukemia treated with all-trans retinoic Acid. Retin Cases Brief Rep. Winter 2013;7(1):46–9.

Crossref  PubMed

38.Newman AR, Leung B, Richards A, Campbell TG, Wellwood J, Imrie FR. Two cases of differentiation syndrome with ocular manifestations in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and arsenic trioxide. Am J Ophthalmol Case Rep. 2018;9:106‐111.

Crossref  PubMed

39.Liu X, Wang Z, Zhao C, Wang H, Guo X, Zhou J, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer. 2020 Mar;11(3):810-818.

Crossref  PubMed

40.Eaton JS, et al.  Ocular adverse events associated with antibody–drug conjugates in human clinical trials.  J Ocul Pharmacol Ther. 2015 Dec;31(10):589-604.

Crossref  PubMed

 
 

Автори засвідчують про відсутність конфлікту інтересів, які б могли вплинути на їх думку стосовно предмету чи матеріалів, описаних та обговорених в даному рукопису. 

Поступила 02.11.2020